InvestorService: Genmab, to Present at 2007 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference

February 05, 2007 02:13 ET | Source: Genmab A/S Genmab A/S

Genmab's CEO will present at the 2007 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City on February 7.

Attachments

102611.pdf...

Recommended Reading

July 15, 2026 06:22 ET | Source: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026

Company Announcement Net sales of DARZALEX® in the second quarter of 2026 totaled USD 4,207 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity...
Read More
July 06, 2026 13:59 ET | Source: Genmab A/S

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Media ReleaseCOPENHAGEN, Denmark; July 6, 2026 TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of...
Read More

$Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma$